Prevention and management of cerebral small vessel disease

Journal of Stroke

Volumn 17, Issue 2, 2015, Pages 111-122

  Mok, Vincent ^a   Kim, Jong S ^b  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b University of Ulsan   (South Korea)

Author keywords

Prevention; Small vessel disease; Treatment

Indexed keywords

ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID PLUS CLOPIDOGREL; ANTIHYPERTENSIVE AGENT; APOENZYME; ATORVASTATIN; CILOSTAZOL; CYANOCOBALAMIN; FOLIC ACID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TISSUE PLASMINOGEN ACTIVATOR; TRIACYLGLYCEROL; TRIFLUSAL;

ARTICLE; BLOOD CLOT LYSIS; BLOOD PRESSURE; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CEREBROVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL (TOPIC); DYSLIPIDEMIA; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; LACUNAR STROKE; LEUKOARAIOSIS; META ANALYSIS (TOPIC); MICROANGIOPATHY; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; NUCLEAR MAGNETIC RESONANCE IMAGING; RANKIN SCALE; RISK FACTOR; SYSTEMATIC REVIEW (TOPIC); SYSTOLIC BLOOD PRESSURE; VASCULAR AMYLOIDOSIS; WHITE MATTER HYPERINTENSITIES;

EID: 84937570403     PISSN: 22876391     EISSN: 22876405     Source Type: Journal    
DOI: 10.5853/jos.2015.17.2.111     Document Type: Article

References (104)

1. Debette S, Markus HS. The clinical importance of white mat­ter hyperintensities on brain magnetic resonance imaging: Systematic review and meta-analysis. BMJ 2010;341:c3666.
2. Altmann-Schneider I, Trompet S, de Craen AJ, van Es AC, Jukema JW, Stott DJ, et al. Cerebral microbleeds are predic­tive of mortality in the elderly. Stroke 2011;42:638-644.
3. Wardlaw JM, Smith EE, Biessels GJ, Cordonnier C, Fazekas F, Frayne R, et al. Neuroimaging standards for research into small vessel disease and its contribution to ageing and neuro­degeneration. Lancet Neurol 2013;12:822-838.
4. Khan U, Porteous L, Hassan A, Markus HS. Risk factor pro­file of cerebral small vessel disease and its subtypes. J Neurol Neurosurg Psychiatry 2007;78:702-706.
5. Boiten J, Lodder J, Kessels F. Two clinically distinct lacunar infarct entities? A hypothesis. Stroke 1993;24:652-656.
6. Arauz A, Murillo L, Cantu C, Barinagarrementeria F, Higuera J. Prospective study of single and multiple lacunar infarcts us­ing magnetic resonance imaging: risk factors, recurrence, and outcome in 175 consecutive cases. Stroke 2003;34:2453-2458.
7. Nah HW, Kang DW, Kwon SU, Kim JS. Diversity of single small subcortical infarctions according to infarct location and parent artery disease: analysis of indicators for small vessel disease and atherosclerosis. Stroke 2010;41:2822-2827.
8. Longstreth WT, Jr, Bernick C, Manolio TA, Bryan N, Jungreis CA, Price T R. Lacunar infarcts defined by magnetic reso­nance imaging of 3660 elderly people: the cardiovascular health study. Arch Neurol 1998;55:1217-1225.
9. Bezerra DC, Sharrett AR, Matsushita K, Gottesman RF, Shi­bata D, Mosley T H Jr, et al. Risk factors for lacune subtypes in the atherosclerosis risk in communities (aric) study. Neurolo­gy 2012;78:102-108.
10. van Dijk EJ, Prins ND, Vrooman HA, Hofman A, Koudstaal PJ, Breteler M M. Progression of cerebral small vessel disease in relation to risk factors and cognitive consequences: Rotter­dam Scan study. Stroke 2008;39:2712-2719.
11. Gouw AA, van der Flier WM, Fazekas F, van Straaten EC, Pan­toni L, Poggesi A, et al. Progression of white matter hyperinten­sities and incidence of new lacunes over a 3-year period: the Leukoaraiosis and Disability Study. Stroke 2008;39:1414-1420.
12. McQuinn BA, O’Leary DH. White matter lucencies on com­puted tomography, subacute arteriosclerotic encephalopathy (binswanger’s disease), and blood pressure. Stroke 1987;18: 900-905.
13. Sulkava R, Erkinjuntti T. Vascular dementia due to cardiac ar­rhythmias and systemic hypotension. Acta Neurologica Scan­dinavica 1987;76:123-128.
14. Pantoni L, Inzitari D, Pracucci G, Lolli F, Giordano G, Bracco L, et al. Cerebrospinal fluid proteins in patients with leucoara­iosis: possible abnormalities in blood-brain barrier function. J Neurol Sci 1993;115:125-131.
15. Moody DM, Brown WR, Challa VR, Anderson RL. Periven­tricular venous collagenosis: association with leukoaraiosis. Radiology 1995;194:469-476.
16. Conklin J, Silver FL, Mikulis DJ, Mandell DM. Are acute in­farcts the cause of leukoaraiosis? Brain mapping for 16 con­secutive weeks. Ann Neurol 2014;76:899-904.
17. Liao D, Cooper L, Cai J, Toole J, Bryan N, Burke G, et al. The prevalence and severity of white matter lesions, their relation­ship with age, ethnicity, gender, and cardiovascular disease risk factors: the ARIC study. Neuroepidemiology 1997;16: 149-162.
18. Longstreth WT Jr, Manolio TA, Arnold A, Burke GL, Bryan N, Jungreis CA, et al. Clinical correlates of white matter find­ings on cranial magnetic resonance imaging of 3301 elderly people. The Cardiovascular Health Study. Stroke 1996;27: 1274-1282.
19. Jeerakathil T, Wolf PA, Beiser A, Massaro J, Seshadri S, D’Agostino RB, et al. Stroke risk profile predicts white matter hyperintensity volume: the Framingham Study. Stroke 2004; 35:1857-1861.
20. de Leeuw FE, de Groot JC, Oudkerk M, Witteman JC, Hof­man A, van Gijn J, et al. Hypertension and cerebral white matter lesions in a prospective cohort study. Brain 2002;125: 765-772.
21. Dufouil C, de Kersaint-Gilly A, Besancon V, Levy C, Auffray E, Brunnereau L, et al. Longitudinal study of blood pressure and white matter hyperintensities: the EVA MRI cohort. Neu­rology 2001;56:921-926.
22. van Dijk EJ, Breteler MM, Schmidt R, Berger K, Nilsson LG, Oudkerk M, et al. The association between blood pressure, hypertension, and cerebral white matter lesions: cardiovascu­lar determinants of dementia study. Hypertension 2004;44: 625-630.
23. Bakker SL, de Leeuw FE, de Groot JC, Hofman A, Koudstaal PJ, Breteler MM. Cerebral vasomotor reactivity and cerebral white matter lesions in the elderly. Neurology 1999;52:578-583.
24. Mok V, Xiong Y, Wong KK, Wong A, Schmidt R, Chu WW, et al. Predictors for cognitive decline in patients with confluent white matter hyperintensities. Alzheimers Dement 2012; 8(Suppl):S96-S103
25. Brickman AM, Reitz C, Luchsinger JA, Manly JJ, Schupf N, Muraskin J, et al. Long-term blood pressure fluctuation and cerebrovascular disease in an elderly cohort. Arch Neurol 2010; 67:564-569.
26. Goldstein IB, Bartzokis G, Hance DB, Shapiro D. Relationship between blood pressure and subcortical lesions in healthy el­derly people. Stroke 1998;29:765-772.
27. Ylikoski A, Erkinjuntti T, Raininko R, Sarna S, Sulkava R, Til­vis R. White matter hyperintensities on mri in the neurologi­cally nondiseased elderly. Analysis of cohorts of consecutive subjects aged 55 to 85 years living at home. Stroke 1995;26: 1171-1177.
28. Vermeer SE, van Dijk EJ, Koudstaal PJ, Oudkerk M, Hofman A, Clarke R, et al. Homocysteine, silent brain infarcts, and white matter lesions: The Rotterdam Scan study. Ann Neurol 2002;51:285-289.
29. Hassan A, Hunt BJ, O’Sullivan M, Bell R, D’Souza R, Jeffery S, et al. Homocysteine is a risk factor for cerebral small vessel disease, acting via endothelial dysfunction. Brain 2004;127: 212-219.
30. de Lau LM, Smith AD, Refsum H, Johnston C, Breteler MM. Plasma vitamin B12 status and cerebral white-matter lesions. J Neurol Neurosurg Psychiatry 2009;80:149-157.
31. de Lau LM, Refsum H, Smith AD, Johnston C, Breteler M M. Plasma folate concentration and cognitive performance: Rot­terdam scan study. Am J Clin Nutrition 2007;86:728-734.
32. Longstreth WT Jr, Katz R, Olson J, Bernick C, Carr JJ, Ma­linow M R, et al. Plasma total homocysteine levels and cranial magnetic resonance imaging findings in elderly persons: the cardiovascular health study. Arch Neurol 2004;61:67-72.
33. Vuorinen M, Solomon A, Rovio S, Nieminen L, Kareholt I, Tuomilehto J, et al. Changes in vascular risk factors from midlife to late life and white matter lesions: a 20-year follow-up study. Dementia Geriatr Cog Disorders 2011;31:119-125.
34. Carmelli D, Swan GE, Reed T, Wolf PA, Miller BL, DeCarli C. Midlife cardiovascular risk factors and brain morphology in identical older male twins. Neurology 1999;52:1119-1124.
35. Schmidt R, Hayn M, Fazekas F, Kapeller P, Esterbauer H. Magnetic resonance imaging white matter hyperintensities in clinically normal elderly individuals. Correlations with plas­ma concentrations of naturally occurring antioxidants. Stroke 1996;27:2043-2047.
36. Jimenez-Conde J, Biffi A, Rahman R, Kanakis A, Butler C, Sonni S, et al. Hyperlipidemia and reduced white matter hy­perintensity volume in patients with ischemic stroke. Stroke 2010;41:437-442.
37. Xu H, Stamova B, Jickling G, Tian Y, Zhan X, Ander BP, et al. Distinctive RNA expression profiles in blood associated with white matter hyperintensities in brain. Stroke 2010;41:2744-2749.
38. Simpson JE, Hosny O, Wharton SB, Heath PR, Holden H, Fernando MS, et al. Microarray rna expression analysis of ce­rebral white matter lesions reveals changes in multiple func­tional pathways. Stroke 2009;40:369-375.
39. Fornage M, Debette S, Bis JC, Schmidt H, Ikram MA, Dufouil C, et al. Genome-wide association studies of cerebral white matter lesion burden: the charge consortium. Ann Neurology 2011;69:928-939.
40. Schmidt R, Enzinger C, Ropele S, Schmidt H, Fazekas F. Pro­gression of cerebral white matter lesions: 6-year results of the Austrian Stroke Prevention Study. Lancet 2003;361:2046-2048.
41. Markus HS, Hunt B, Palmer K, Enzinger C, Schmidt H, Schmidt R. Markers of endothelial and hemostatic activation and pro­gression of cerebral white matter hyperintensities: Longitudinal results of the Austrian Stroke Prevention Study. Stroke 2005;36: 1410-1414.
42. Longstreth WT Jr, Arnold AM, Beauchamp NJ Jr, Manolio TA, Lefkowitz D, Jungreis C, et al. Incidence, manifestations, and predictors of worsening white matter on serial cranial magnetic resonance imaging in the elderly: The Cardiovascu­lar Health Study. Stroke 2005;36:56-61.
43. Godin O, Tzourio C, Maillard P, Mazoyer B, Dufouil C. Anti­hypertensive treatment and change in blood pressure are as­sociated with the progression of white matter lesion volumes: The three-city (3c)-dijon magnetic resonance imaging study. Circulation 2011;123:266-273.
44. Gottesman RF, Coresh J, Catellier DJ, Sharrett AR, Rose KM, Coker LH, et al. Blood pressure and white-matter disease pro­gression in a biethnic cohort: atherosclerosis Risk In Commu­nities (ARIC) study. Stroke 2010;41:3-8.
45. Xiong Y, Wong A, Cavalieri M, Schmidt R, Chu WW, Liu X, et al. Prestroke statins, progression of white matter hyperin­tensities, and cognitive decline in stroke patients with conflu­ent white matter hyperintensities. Neurotherapeutics 2014;11: 606-611.
46. van Dijk EJ, Prins ND, Vermeer SE, Vrooman HA, Hofman A, Koudstaal PJ, et al. C-reactive protein and cerebral small-vessel disease: the Rotterdam Scan study. Circulation 2005; 112:900-905.
47. Schmidt R, Schmidt H, Pichler M, Enzinger C, Petrovic K, Niederkorn K, et al. C-reactive protein, carotid atherosclero­sis, and cerebral small-vessel disease: results of the Austrian Stroke Prevention Study. Stroke 2006;37:2910-2916.
48. Wang Z, Soo YO, Mok VC. Cerebral microbleeds: is antithrom­botic therapy safe to administer? Stroke 2014;45:2811-2817.
49. Cordonnier C, Al-Shahi Salman R, Wardlaw J. Spontaneous brain microbleeds: systematic review, subgroup analyses and standards for study design and reporting. Brain 2007;130: 1988-2003.
50. Poels MM, Vernooij MW, Ikram MA, Hofman A, Krestin GP, van der Lugt A, et al. Prevalence and risk factors of cerebral microbleeds: an update of the Rotterdam Scan study. Stroke 2010;41:S103-106.
51. Staals J, van Oostenbrugge RJ, Knottnerus IL, Rouhl RP, Hen­skens LH, Lodder J. Brain microbleeds relate to higher ambu­latory blood pressure levels in first-ever lacunar stroke patients. Stroke2009;40:3264-3268.
52. Park JH, Ryoo S, Kim SJ, Kim GM, Chung CS, Lee KH, et al. Differential risk factors for lacunar stroke depending on the mri (white and red) subtypes of microangiopathy. PLoS One 2012;7:e44865.
53. Lee SH, Bae HJ, Yoon BW, Kim H, Kim DE, Roh JK. Low concentration of serum total cholesterol is associated with multifocal signal loss lesions on gradient-echo magnetic reso­nance imaging: analysis of risk factors for multifocal signal loss lesions. Stroke 2002;33:2845-2849.
54. Wieberdink RG, Poels MM, Vernooij MW, Koudstaal PJ, Hofman A, van der Lugt A, et al. Serum lipid levels and the risk of intracerebral hemorrhage: the Rotterdam study. Arte­rioscler Thromb Vasc Biology 2011;31:2982-2989.
55. Haussen DC, Henninger N, Kumar S, Selim M. Statin use and microbleeds in patients with spontaneous intracerebral hemorrhage. Stroke 2012;43:2677-2681.
56. Day JS, Policeni BA, Smoker WR, Dobre MC, Zhang Y, Leira EC, et al. Previous statin use is not associated with an increased prevalence or degree of gradient-echo lesions in patients with acute ischemic stroke or transient ischemic attack. Stroke 2011;42:354-358.
57. Ovbiagele B, Liebeskind DS, Pineda S, Saver J L. Strong inde­pendent correlation of proteinuria with cerebral microbleeds in patients with stroke and transient ischemic attack. Arch Neurol 2010;67:45-50.
58. Maxwell SS, Jackson CA, Paternoster L, Cordonnier C, Thijs V, Al-Shahi Salman R, et al. Genetic associations with brain microbleeds: systematic review and meta-analyses. Neurology 2011;77:158-167.
59. Gregoire SM, Brown MM, Kallis C, Jager HR, Yousry TA, Werring DJ. MRI detection of new microbleeds in patients with ischemic stroke: five-year cohort follow-up study. Stroke 2010;41:184-186.
60. Poels MM, Ikram MA, van der Lugt A, Hofman A, Krestin GP, Breteler MM, et al. Incidence of cerebral microbleeds in the general population: the Rotterdam Scan study. Stroke 2011;42:656-661.
61. Goos JD, Henneman WJ, Sluimer JD, Vrenken H, Sluimer IC, Barkhof F, et al. Incidence of cerebral microbleeds: a longitu­dinal study in a memory clinic population. Neurology 2010; 74:1954-1960.
62. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333:1581-1587.
63. Hsia AW, Sachdev HS, Tomlinson J, Hamilton SA, Tong DC. Efficacy of IV tissue plasminogen activator in acute stroke: does stroke subtype really matter? Neurology 2003;61:71-75.
64. Fluri F, Hatz F, Rutgers MP, Georgiadis D, Sekoranja L, Schwe­gler G, et al. Intravenous thrombolysis in patients with stroke attributable to small artery occlusion. Eur J Neurol 2010;17: 1054-1060.
65. Mustanoja S, Meretoja A, Putaala J, Viitanen V, Curtze S, Atu­la S, et al. Outcome by stroke etiology in patients receiving thrombolytic treatment: Descriptive subtype analysis. Stroke 2011;42:102-106.
66. Fuentes B, Martinez-Sanchez P, Alonso de Lecinana M, Egi­do J, Reig Rosello G, Diaz Otero F, et al. Efficacy of intrave­nous thrombolysis according to stroke subtypes: the Madrid Stroke Network Data. Eur J Neurol 2012;19:1568-1574.
67. Shobha N, Fang J, Hill MD. Do lacunar strokes benefit from thrombolysis? Evidence from the registry of the Canadian Stroke Network. Int J Stroke 2013;8(Suppl):45-49
68. Jauch EC, Saver JL, Adams HP Jr, Bruno A, Connors JJ, De­maerschalk B M, et al. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/Ameri­can Stroke Association. Stroke 2013;44:870-947.
69. Pantoni L, Fierini F, Poggesi A. Thrombolysis in acute stroke patients with cerebral small vessel disease. Cerebrovasc Dis 2014;37:5-13.
70. Neumann-Haefelin T, Hoelig S, Berkefeld J, Fiehler J, Gass A, Humpich M, et al. Leukoaraiosis is a risk factor for symptom­atic intracerebral hemorrhage after thrombolysis for acute stroke. Stroke 2006;37:2463-2466.
71. Palumbo V, Boulanger JM, Hill MD, Inzitari D, Buchan AM. Leukoaraiosis and intracerebral hemorrhage after thromboly­sis in acute stroke. Neurology 2007;68:1020-1024.
72. Demchuk AM, Khan F, Hill MD, Barber PA, Silver B, Patel S, et al. Importance of leukoaraiosis on ct for tissue plasminogen activator decision making: evaluation of the NINDS rt-PA Stroke Study. Cerebrovasc Dis 2008;26:120-125.
73. Aries MJ, Uyttenboogaart M, Vroomen PC, De Keyser J, Luijckx GJ. Tpa treatment for acute ischaemic stroke in patients with leukoaraiosis. Eur J Neurol 2010;17:866-870.
74. Chalela JA, Kang DW, Warach S. Multiple cerebral micro­bleeds: mri marker of a diffuse hemorrhage-prone state. J Neuroimaging 2004;14:54-57.
75. Fiehler J, Albers GW, Boulanger JM, Derex L, Gass A, Hjort N, et al. Bleeding risk analysis in stroke imaging before throm­bolysis (brasil): pooled analysis of T2*-weighted magnetic resonance imaging data from 570 patients. Stroke 2007;38: 2738-2744.
76. Charidimou A, Kakar P, Fox Z, Werring DJ. Cerebral micro­bleeds and the risk of intracerebral haemorrhage after throm­bolysis for acute ischaemic stroke: systematic review and me­ta-analysis. J Neurol Neurosurg Psychiatry 2013;84:277-280.
77. Dannenberg S, Scheitz JF, Rozanski M, Erdur H, Brunecker P, Werring DJ, et al. Number of cerebral microbleeds and risk of intracerebral hemorrhage after intravenous thrombolysis. Stroke 2014;45:2900-2905.
78. Progress Management Committee. PROGRESS-Perindopril protection Against Recurrent Stroke Study: characteristics of the study population at baseline. J Hypertens 1999;17:1647-1655.
79. Gueyffier F, Boissel JP, Boutitie F, Pocock S, Coope J, Cutler J, et al. Effect of antihypertensive treatment in patients having already suffered from stroke. Gathering the evidence. The INDANA (INdividual dData ANalysis of Antihypertensive intervention trials) project collaborators. Stroke 1997;28: 2557-2562.
80. Rashid P, Leonardi-Bee J, Bath P. Blood pressure reduction and secondary prevention of stroke and other vascular events: a systematic review. Stroke 2003;34:2741-2748.
81. Benavente OR, Hart RG, McClure LA, Szychowski JM, Cof­fey CS, Pearce L A. Effects of clopidogrel added to aspirin in patients with recent lacunar stroke. N Engl J Med 2012;367: 817-825.
82. Benavente OR, Coffey CS, Conwit R, Hart RG, McClure LA, Pearce LA, et al. Blood-pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial. Lancet 2013;382: 507-515.
83. Dufouil C, Chalmers J, Coskun O, Besancon V, Bousser MG, Guillon P, et al. Effects of blood pressure lowering on cerebral white matter hyperintensities in patients with stroke: the PROGRESS (Perindopril pROtection aGainst REcurrent Stroke Study) magnetic resonance imaging substudy. Circula­tion. 2005;112:1644-1650.
84. Muller M, Sigurdsson S, Kjartansson O, Aspelund T, Lopez OL, Jonnson PV, et al. Joint effect of mid- and late-life blood pressure on the brain: the Ages-Reykjavik study. Neurology 2014;82:2187-2195.
85. Amarenco P, Benavente O, Goldstein LB, Callahan A 3rd, Sil­lesen H, Hennerici MG, et al. Results of the stroke prevention by aggressive reduction in cholesterol levels (SPARCL) trial by stroke subtypes. Stroke 2009;40:1405-1409.
86. Goldstein LB, Amarenco P, Szarek M, Callahan A 3rd, Hennerici M, Sillesen H, et al. Hemorrhagic stroke in the stroke prevention by aggressive reduction in cholesterol levels study. Neurology 2008;70:2364-2370.
87. Furie KL, Kasner SE, Adams RJ, Albers GW, Bush RL, Fagan SC, et al. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: A guideline for health­care professionals from the American Heart Association/American Stroke Association. Stroke 2011;42:227-276.
88. Mok VC, Lam WW, Fan YH, Wong A, Ng PW, Tsoi TH, et al. Effects of statins on the progression of cerebral white mat­ter lesion: post hoc analysis of the ROCAS (Regression Of Cerebral Artery Stenosis) study. J Neurol 2009;256:750-757.
89. Fu JH, Mok V, Lam W, Wong A, Chu W, Xiong Y, et al. Ef­fects of statins on progression of subclinical brain infarct. Cerebrovasc Dis 2010;30:51-56.
90. Cavalieri M, Schmidt R, Chen C, Mok V, de Freitas GR, Song S, et al. B vitamins and magnetic resonance imaging-detected ischemic brain lesions in patients with recent transient isch­emic attack or stroke: the VITAmins TO Prevent Stroke (VI­TATOPS) MRI-substudy. Stroke 2012;43:3266-3270.
91. Gopalan Y, Shuaib IL, Magosso E, Ansari MA, Abu Bakar MR, Wong JW, et al. Clinical investigation of the protective effects of palm vitamin E tocotrienols on brain white matter. Stroke 2014;45:1422-1428.
92. Bousser MG, Eschwege E, Haguenau M, Lefaucconnier JM, Thibult N, Touboul D, et al. “AICLA” controlled trial of aspi­rin and dipyridamole in the secondary prevention of athero-thrombotic cerebral ischemia. Stroke 1983;14:5-14.
93. Gent M, Blakely JA, Easton JD, Ellis DJ, Hachinski VC, Harbi­son J W, et al. The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet 1989;1:1215-1220.
94. Gorelick PB, Richardson D, Kelly M, Ruland S, Hung E, Har­ris Y, et al. Aspirin and ticlopidine for prevention of recurrent stroke in black patients: A randomized trial. JAMA 2003; 289:2947-2957.
95. Halkes PH, van Gijn J, Kappelle LJ, Koudstaal PJ, Algra A. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised con­trolled trial. Lancet 2006;367:1665-1673.
96. Nonaka Y, Tsuruma K, Shimazawa M, Yoshimura S, Iwama T, Hara H. Cilostazol protects against hemorrhagic transforma­tion in mice transient focal cerebral ischemia-induced brain damage. Neurosci Lett 2009;452:156-161.
97. Huang Y, Cheng Y, Wu J, Li Y, Xu E, Hong Z, et al. Cilostazol as an alternative to aspirin after ischaemic stroke: a randomised, double-blind, pilot study. Lancet Neurol 2008;7:494-499.
98. Shinohara Y, Katayama Y, Uchiyama S, Yamaguchi T, Handa S, Matsuoka K, et al. Cilostazol for Prevention of Secondary Stroke (CSPS2): an aspirin-controlled, double-blind, ran­domised non-inferiority trial. Lancet Neurol 2010;9:959-968.
99. Wilhite DB, Comerota AJ, Schmieder FA, Throm RC, Gaughan JP, Rao AK. Managing pad with multiple platelet in­hibitors: the effect of combination therapy on bleeding time. J Vasc Surg 2003;38:710-713.
100. Lee JH, Kim KY, Lee YK, Park SY, Kim CD, Lee WS, et al. Ci­lostazol prevents focal cerebral ischemic injury by enhancing casein kinase 2 phosphorylation and suppression of phospha­tase and tensin homolog deleted from chromosome 10 phos­phorylation in rats. J Pharmacol Exp Ther 2004;308:896-903.
101. Kasahara Y, Nakagomi T, Matsuyama T, Stern D, Taguchi A. Cilostazol reduces the risk of hemorrhagic infarction after ad­ministration of tissue-type plasminogen activator in a murine stroke model. Stroke 2012;43:499-506.
102. Uchiyama S, Shinohara Y, Katayama Y, Yamaguchi T, Handa S, Matsuoka K, et al. Benefit of cilostazol in patients with high risk of bleeding: subanalysis of cilostazol stroke prevention study 2. Cerebrovasc Dis 2014;37:296-303.
103. Han SW, Song TJ, Bushnell CD, Lee SS, Kim SH, Lee JH, et al. Cilostazol decreases cerebral arterial pulsatility in patients with mild white matter hyperintensities: subgroup analysis from the effect of cilostazol in acute lacunar infarction based on pulsatility index of transcranial doppler (ECLIPse) study. Cerebrovasc Dis 2014;38:197-203.
104. Culebras A, Rotta-Escalante R, Vila J, Dominguez R, Abiusi G, Famulari A, et al. Triflusal vs aspirin for prevention of cere­bral infarction: a randomized stroke study. Neurology 2004; 62:1073-1080.